Drug Profile
Research programme: chemokine therapeutics - Biokine Therapeutics
Alternative Names: BKT 130; BKT-RP3Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Biokine Therapeutics
- Class Antibodies
- Mechanism of Action Chemokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in Israel
- 20 Sep 2017 Discontinued - Preclinical for Multiple sclerosis in Israel (IV)
- 20 Sep 2017 Discontinued - Preclinical for Rheumatoid arthritis in Israel (IV)